<DOC>
	<DOCNO>NCT02702583</DOCNO>
	<brief_summary>Febrile neutropenia ( FN ) clinically important adverse effect myelosuppressive chemotherapy . If patient present FN , attention focus well-recognized site origin infection : airway , urinary tract , skin . However , infection document clinically two-third febrile episode , whereas causative microbial pathogen identify majority ( &gt; 70 % ) case . Pre-treatment oral evaluation aim identify eliminate oral/dental focus routinely use patient high risk oral complication ( i.e . head neck cancer patient stem cell transplantation recipient ) . However , patient treat myelosuppressive chemotherapy , cure palliation , risk develop infection and/or originate oral cavity . Nevertheless , patient dental screen somewhat randomly employ oncologist 's discretion . More insight pre-treatment oral condition potential role FN mandatory , particularly consider grow number old patient retain natural dentition increase dental diseases cancer incidence age . In addition , oral disease may aggravate chemotherapy-induced oral mucositis ( OM ) . OM associate inflammatory response , together ulceration provide portal entry bacteria , result FN systemic inflammatory syndrome ( SIRS ) and/or sepsis . Evidence suggest microorganism involve pathobiology OM , longitudinal study use open-end sequencing available . Furthermore , compare bacteria identify blood culture febrile patient oral cavity expand knowledge role oral cavity potential source bacteremia . The investigator expect result provide scientific base subsequent intervention study efficacy dental screen elimination focus , intervention aim modify oral environment chemotherapy .</brief_summary>
	<brief_title>The Oral Cavity Source Febrile Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>Diagnosed solid cancer , lymphoma multiple myeloma Planned treatment myelosuppressive chemotherapy FN risk 10 % 20 % ( without target therapy hormonal therapy ) Willing able give write Informed consent Age 18 old Presence ( partial ) natural dentition and/or dental implant Patients unable give write informed consent Patients &lt; 18 year Prior irradiation head neck Edentulous patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Myelosuppressive Chemotherapy</keyword>
	<keyword>Febrile Neutropenia</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Dental Infection</keyword>
	<keyword>Oral Infection</keyword>
</DOC>